This week’s list is not as long as that posted last week..I didn’t want to hold many of the jobs I got after I posted initially on the 30th so that list was huge.

Feel free to send to you friends who might want this type of information if its content isn’t of special interest to you.

Note that the downloadable list includes 3 weeks of posted jobs with contact names and some helps for those looking to change positions. Jobs That Crossed My Desk Through Feb.7_2010FIN

Happy hunting!

Audrey

Money is on everyone’s mind–the government, nonprofits, for-profit companies and professionals in the life science industry, especially, entrepreneurs looking for Round A funding. I suggest you keep your eyes open for the many meetings focusing on raising investment funds and/or reporting on potential IPOs. There are several general as opposed to bioscience events on raising money which I haven’t listed this week as I’ve found that the panel typically speaks to the high tech industry events and experiences. Even when the topic is the “Moneytree” and life sciences are the #1 sector in venture capita fundingl in the report, a panel recruited from high tech VCs and/or companies don’t speak about  much of interest to us in life science companies.  I attended such a meeting last week and came away with some limited data  of interest from the PriceWaterhouse Cooper’s speaker’s short presentation.

Biotechnology(#1)  in VC funding received $3,543.3 million in 406 deals while Medical Devices and Equipment (#3 sector) received $2,502.3 million in 309 deals in 2009. The funds raised were down by 18.57% and 26.55% , respectively, versus 2008. Health care services received $102.4 million with 33 deals and declined 43.94% versus 2008. You can read press release on the 4th Quarter Moneytree report at https://www.pwcmoneytree.com/MTPublic/ns/moneytree/filesource/exhibits/09Q4MTRelease_FINAL.pdf.

For what’s happening in our California industry, I suggest you read the latest California’s Biomedical Report 2010 by PWC and California Health Institute found at http://www.pwc.com/en_GX/gx/pharma-life-sciences/forms/chireport2010.jhtml. It’s Executive Summary is available at  http://www.chi.org/uploadedFiles/Executive_Summary_2010_California_Biomedical_Industry_Report_FINAL.PDF. This report is totally focused on the life science industry in California.

This week’s meetings include two with a financial/fundraising focus.  See list of selected events below and details in the downloadable Word document MeetingListFeb6_10 Events through March are included.

• Bay Bio Medical Device Breakfast, Tuesday Morning, Feb. 9, 2010, Topic: “Company Valuation for M&A,” Moderator: Mark Weeks, Partner, Cooley Godward Kronish LLP, Panel Speakers: Jason Yip, Principal, Montgomery & Co., LLC and Jeffrey Gold, Venture Partner, Longitude Capital, Former CEO, CryoVascular Systems

• Bio2Device Group, Tuesday Evening, Feb. 9, 2010, Topic: “A molecular diagnostic company’s journey from science to product – Providing the answer to the fundamental question -What type of cancer is it?” Speaker: Deb Neff, President and CEO, Pathwork Diagnostics

• BayBioNEST Venture Spotlight, Thursday Morning, Feb. 11, 2010, Topic:”A Sweet Deal: How to Attract Investors”

• San Jose BioCenter All About Science Series, Thursday Afternoon, Feb. 11, 2010, Topic: “Effective outsourcing: Navigating hurdles and avoiding pitfalls in virtual drug development” The panel will include: Kate Hanham, Ph.D., President & Founder, Mentara, Inc., a consulting consortium of highly qualified drug/device discovery and development professionals; Richard Lin, President, Explora Biolabs, Inc., which provides vivarium and pre-clinical in vivo contract research services; and Fred Aslan, M.D., Vice President, Venrock: an investor experienced in starting and running virtual companies.
  

• UCSC Ext. Bioscience Product Marketing, Thursday Evenings, Feb. 11 – March 25, 2010, Lead Instructor: Audrey Erbes, Ph.D., Principal, Erbes & Associates;  Guest Speakers: Chris Mahoney, MPA, WebMD; Alan Hirshman, Senior Principal, Commercial Effectiveness, IMS Health; Stanley Skrzypczak, M.B.A., Director, Managed Care Marketing, Genomic Health; Charles Versaggi, Ph.D.,President of Versaggi Biocommunications®; Steven Wong, B.A.,  Senior Consultant at Plan A. Additional Guest Speakers with Short Presentations: Tais Schmitt, Ph.D.; Debbie Donovan, Consultant at eGold Solutions; Erik Haghjoo, Ph.D., Consultant in the Life Sciences division of Simon-Kucher & Partners

• Palo Alto AWIS, Thursday Evening, Feb. 11, 2010, Topic: “Real-Life CSI,” Speaker: Cordelia Willis, Criminalist, Santa Clara County Crime Laboratory

Audrey

The number of jobs has picked up in tune with comments I’ve heard from recruiters in recent weeks. I’ve attached my most recent list of jobs for the past week plus those from two weeks earlier for total of  three weeks.

I’ve  provided the list as a downloadable Word document Jobs That Crossed My Desk Through Jan31_2010REV (right click and open in new window)

Don’t forget to review jobs on the Bio2Device Group website and other job sites listed at end of my weekly report.

Audrey

Another week with interesting opportunities to network and learn about financing and competitors  lies ahead.  Here are my picks of the week:

• Bio2Device Group, Tuesday Morning, Feb. 2, 2010 – Topic: “Molecular Image – fundraising in a tough environment,” Speaker: Russ Singleton , Molecular Image, (note at TIPS this week-no registration required)

• San Jose BioCenter, Tuesday Mid-Day, Feb. 2, 2010 – Program: “Planning for Your Drug Development Success: From the Bench to the Clinic;”  Speakers: Dr. Richard Slauter, Senior Director of Drug Metabolism and Pharmacokinetics, MPI Research, Inc., Dr. Brian Rogers, VP of Toxicology, Pacific BioDevelopment, Dr. Stephen Frantz, Director of Business Development, Pacific Northwest, MPI Research, Inc., Dr. David Brewster, Sr. Safety Expert for Global NonClinical Safety and Head External Relations, US, F. Hoffman-La Roche
• CABS, Tuesday Evening, Feb. 2, 2010 – Seminar & Round-Table: “Investor Pitch: How to Get Funding for Your Great Idea”

• CSPA, Tuesday Evening, Feb. 2, 2010 – Topic: “Venture Capital Outlook 2010”, Panel: David Lane -  General Partner, Onset Ventures, Prashant Shah – Managing Director, Hummer Winblad Venture Partner, John Steuart – Managing Director, Claremont Creek Ventures, Hing Wong – Managing Director, Walden International

• Tri-Conference, Wednesday and Thursday, Feb. 3-4, 2010 (sign up for free hall pass and hear plenary session speakers and visit exhibit hall)

• BioE2E Biotech Entrepreneurs Program, Wednesday Evening, Feb. 3, 2010 – Topic: “Important Early Steps in Setting up Your Business, ” Speakers: Bruce Cohen, MD, Founder, President & CEO VistaPath Genetics, Bill Starling, co-founder of Synergy Life Science Partners, Paul A. Stone, General Counsel and Chief Operating Officer, 5AM Ventures

• Triple Ring Technologies, Thursday Evening, Feb. 4, 2010 – Topic: ” Fluoroscopy and Angiography for Treatment of Children with Congenital Heart Disease: Current Use and Future Needs,” Speaker: Dr. Phillip Moore, director of the Pediatric Cardiac Catheterization   Laboratory at UCSF Children’s Hospital

Details for these meetings can be found in downloadable Word document MeetingListJan31_10 which includes February-March meetings.

It’s not too late to sign up for UCSC Extension in Silicon Valley’s course Bioscience Product Marketing (starts Thursday evening Feb. 11th)  where you can learn how to research and write a life science product marketing plan.

Hope you’ve survived the weather with little damage and hope to see you at one of these upcoming events. My insurance agent advised me that there are  over 5,000 claims in California qualifying the state as catastrophe area!  Stay dry wherever you are.

Audrey

We have another healthy list of activities this coming week. Highlights include:

• FountainBlue Life Science Entrepreneur’s Forum, Monday Evening, Jan. 25, 2010, Topic: Life Science Angel Investor’s Panel: Trends for 2010
• UCSC Ext. Sequence Analysis in Bioinformatics, Advanced, Jan. 25 – March 29, 2010, www.ucsc-extension.edu/biosciences
• Bio2Device Group, Tuesday Morning, Jan. 26, 2010, Topic: “Key Drivers of Reimbursement Strategy Development & Planning for Medical Devices,” Speaker: Sue Rowinski, Sue Rowinski, LLC
• CABS, Tuesday Evening, Jan. 26, 2010, Seminar & Round-Table: “Business Plan & Executive: How to Lay Out Your Great Idea”
• Northern Silicon Valley Partnership, Wednesday Morning, Jan. 27, 2010, Topic: “Free Entrepreneur Pitch Event to Angel Investors: Green technology, biotechnology, information technology, and sustainable products or services”
• BayBio Therapeutic Breakfast Series, Thursday, Jan. 28, 2010, Topic: “Planning for Success: The Balance Between Clinical Trial Design and Implementation”
• East Bay AWIS, Thursday Evening, Jan. 28, 2010, Event: January Chapter Meeting
• Deadline for discount for my UCSC Extension Bioscience Product Marketing course. See details in blog earlier today.

See full list of industry meetings for January-February at downloadable Word document with right click MeetingListJan24_10 .

Audrey

Jobs are picking up and I’m hearing that from recruiters in all bioscience sectors. Here’s the latest jobs for this past week that crossed my desk. See all for month in the downloadable Word file Jobs That Crossed My Desk Through Jan24_2010 (right click to open) as well as helpful hints and listing of next Career Fair in Bay Area.

Be sure to see those jobs listed on Bio2Device Group’s website at www.bio2devicegroup.org as well. They are different.

Remember that the discounted price for my UCSC Ext. course in Bioscience Product Marketing ends Thursday, Jan. 28th. This is great opportunity to add a product marketing plan to your career portfolio.

Audrey

Course Description

Hi,

We have a great program of topics and speakers lined up for the upcoming evening series of the UCSC Extension’s Bioscience Product Marketing course, Thursdays , Feb. 11 – March 11 and 25th where you’ll have opportunity to learn how to develop a professional quality marketing plan to add to your career portfolio.

See course description and details below with list of outstanding experienced industry professionals who will share their expertise with you–enabling you and your team to develop a preliminary marketing plan for a product of your team’s choice.

Sign up through Jan. 28th and get the early enrollment discount.  See details at www.ucsc-extension.edu/BPM.

I’ve provided bios and listing of talks in posting sent earlier today.

Audrey

UCSC Ext. Bioscience Product Marketing, Thursday Evenings, Feb. 11 – March 25, 2010

This product marketing and selling-focused course gives participants an in-depth look at product planning and research, marketing planning, and promotional execution practices in the bioscience industry. Topics include market research methodologies, information sources and applications relevant to product planning; the development of marketing strategy, product positioning and differentiated claims; and the creation of tactical marketing programs and activities to maximize revenue potential. Course activities include the creation of a preliminary marketing plan.

The course is well suited for all levels of professionals in bioscience marketing research, product management, product sales, advertising, public relations, business development and licensing, as well as other related functions, such as regulatory, clinical and legal.

Guest Speakers:

§         Chris Mahoney, MPA, WebMD, is an expert in the use of secondary patient data for pharmaceutical marketing applications, consulting with companies ranging from large global pharmaceutical companies to start-up biotechnology companies and Alan Hirshman, Senior Principal, Commercial Effectiveness, IMS Health. Before coming to IMS Health, Alan was Vice President of Sales for SDI Health. At SDI he was responsible for West and Midwest sales. “Patient Adherence: The Impact on Brand Performance.”

§         Stanley Skrzypczak, M.B.A., Director, Managed Care Marketing, Genomic Health, has over 25 years of successful biotech and pharmaceutical sales and marketing experience, including product, managed care, clinical marketing and sales management.  Topic – “Product Management 101- Developing/Executing The Tactical Plan”

§         Charles Versaggi, Ph.D., is president of Versaggi Biocommunications®, a strategic marketing consultancy for biotechnology, pharmaceutical and medical technology companies. Topic – “Building Value through Strategic Marketing Planning and Communications.”

§         Steven Wong, B.A., is a senior consultant at Plan A, a strategic marketing consulting firm servicing biotechnology and pharmaceutical companies. At Plan A, he has directed numerous consulting engagements, including opportunity assessments, complex population modeling, and therapeutic area. Topic – “Market Research Information Resources.”

Additional Guest Speakers with Short Presentations:

§         Tais Schmitt, Ph.D. currently pursuing a Certificate in Bioscience Business and Marketing at UCSC Extension, agreed to share her student project experiences for this course which she completed in the winter of 2007. Topic – “Tackling the Marketing Plan Project.”

§         Debbie Donovan, Consultant at eGold Solutions, has worked on client side on products that served the ENT, Orthopedics/Spine, Ob/Gyn and Oncology surgery specialties at Somnus, Kyphon and Conceptus, Inc., and most recently Senior Manager at Intuitive Surgical where she focused on market development programs and e-marketing initiatives. Topic – “E-Marketing: Activating Patients in a Web 2.0 World.”

§         Erik Haghjoo, Ph.D., consultant in the Life Sciences division of Simon-Kucher & Partners, focuses on developing global pricing and positioning strategies for new and existing products.  His project experience includes product launch strategy, value proposition, pricing and reimbursement strategy, and portfolio strategy. Topic – “Role of Pricing and Reimbursement in Product Management Strategic Planning.”

Dates and Times: Thu 6:00PM to 9:30PM
Feb 11, 2010 to Mar 11, 2010
Thu 6:00PM to 9:30PM
Mar 25, 2010
Number of Sessions: 6 (over 7 weeks)

Location: UCSC Extension in Silicon Valley, 2505 Augustine Drive, Santa Clara

Tuition: $700 (Early enrollment – $630 through Jan. 28)

See details at www.ucsc-extension.edu/BPM

Audrey

While developing my promised remarks on JP Morgan’s third day, I ran into the Senate returns in Massachusetts…so here goes.

More Notes from JP Morgan Healthcare Conference, Jan. 13, 2010

Tom Daschle’s luncheon keynote gave a different perspective on health care reform legislation versus the previous day’s talk by Tom Scully, former administrator at Centers for Medicare and Medicaid and General Partner, Welsh, Carson, Anderson & Stowe. The fact that Daschle, Former Senate Majority Leader, is a Democrat provided another viewpoint with different view of the landscape of the debate underway. Where Scully summarized Health Care Reform from his perspective as focused on expanded coverage legislation, Daschle informed the audience that the bills had nothing to do with a Health Care System but rather a Health Care Market reform. He sees the landscape of one of 50%/50% private for-profit and government players, respectively.

As a result of being a “health care market” instead of a health care delivery system, he views the U.S. stakeholders holding difference goals. While U.S. players place emphasis on spending from the top of the pyramid down to bottom, other countries put emphasis on meeting needs at bottom of pyramid and working way up until the money runs out. While universal coverage of citizens is at the “bottom” in the U.S. health care arena, it’s of first order priority in European single-payer system countries. So it’s not surprising that U.S. politicians focus on costs as reason to not provide universal coverage—it’s all about costs not mandate.

As with Scully, Daschle thinks the changes that are needed will take a long time because of the heavy involvement of for-profit motivations in the “market” but that the reforms will eventually occur. He outlined the issues: access, cost, lack of transparency, unnecessary defensive care, insufficient health information technology, etc. and distinguished three components of reform: insurance, payment and delivery reform before speaking to the differences in reaching agreement. Daschle’s quote of Churchill with reference to how Americans will eventually solve the problem of health care had the audience laughing—“Americans can always be counted on to do the right thing…after they have exhausted all other possibilities.”

Endo Pharmaceutics, a specialty pharma company, sounded like they have joined the big pharma chorus in reassuring investors they are transforming themselves. Endo surprised me with their mentioning a focus on specialty generics with interest in in-licensing products and API for planned usage with their implant technology. The company originated as a pain generics company spun out from Dupont Pharmaceuticals with some fantastic good fortune in licensing the patented Lidoderm patch which is a blockbuster dermal pain product for them but, unfortunately, has placed them at risk of too much exposure when that patent runs out. They also indicated a shift to global business—“Endo is transforming to deliver the right treatment solutions focused on consumer-driven medical decisions.”

Myriad Genetics, a public company, along with several other private companies did have positive stories to tell. With a global molecular diagnostics market projected to exceed $6 billion in 2015, Myriad had good news of a 47% growth in revenues in 2009, 87% gross profit margin, plans to increase their current sales force of 300 with another 100 representatives and positioned to launch one new product per year. Theirs is the story of “predictive, personalized and prognostic medicine.”

Complete Genomics, a private company located in Silicon Valley, offered an exciting new business model—a new kind of company with a new big model based on IP-protected DNA sequencing technology. Their unique selling proposition is the highest quality data at lowest cost. They want to be a data rather than services business—meeting the need for sequencing 100s of thousands of human genomes for researchers. Unlike competitors who sell instruments to researchers, they sell data. DNA is sent via Fedex for analysis and human genome report is shipped as output to customer via Internet. They foresee positioning company for IPO in 2010.

Status of Health Care Reform Now

What is health care reform legislation’s future now after the loss of the 60^th filibuster- proofing Democratic vote in Senate from Massachusetts? Democrats fear not passing the legislation at all enough that they just might convince the House to accept the Senate version despite some differences that they don’t like to avoid need for passage of different bill there.

Stay tuned as politics play out. It is clear that Massachusetts voters’ minds were more focused on the state of the economy or anger at failure to curb bankers’ greed than the need for maintaining 60 votes in the Senate for the passage of legislation they otherwise philosophically might support. Even the new Republican Senator Scott Brown voted for the 2006 health care reform legislation in Massachusetts. Perhaps voters wanted a change in Congressional representation that has been all Democratic for so long. They traditionally balance the field with Republican governors like Mitt Romney who fostered the healthcare reforms when as one-term governor there. Or was it low turnout in the urban areas where support for state Attorney General Martha Coakley, the Democratic candidate, was strong.

Audrey

Hi,

Events are prolific once again now that 2010 has started. There are an especially large number of fine life science applied courses that start in January listed for those in the market to sharpen their saw. Organizations have developed some fine fare for all of us to grow in our fields as well as explore other areas of knowledge. I’ve provided identities of groups, topics, speakers and dates below and full details in the downloadable Word file MeetingListJan17_10.  (Right click on file and open in another window.) You can also access the full list on my blog found at www.audreysnetwork.com.

Highlights of this week’s meetings and online events include:

v      Bio2Device Group, Tuesday Morning, Jan. 19, 2010—Topic: “How Companies Identify ‘A’ Players and Positioning Yourself for the Role you Really Want “; Speaker: Laura Raynak, Raynak Executive Search

v      Stanford Cancer Center and NCI workshop, Tuesday Morning, Jan. 19, 2010—Topic: “Integrating Glycomics with Other Omics in Cancer Detection and Diagnosis”

v      Personalized Medicine World Conference, Tuesday and Wednesday, Jan. 19-20, 2010—“Personalized Medicine: The Next Wave Of Innovation!
What Is Available NOW?”

v      Deloitte Recap Free Webinar, Tuesday Morning, Jan. 19, 2010—Topic: “Leading Practices in Co-Promotion Alliances”

v      CABS, Tuesday Evening, Jan. 19, 2010—Seminar & Round-Table: “13 Mistakes Entrepreneurs Should Avoid”

v BioScience Forum, Wednesday Evening, Jan. 20, 2010—Topic: “Genomic and Proteomic Biomarkers that Predict Risk for Diseases and the Outcome of Drug Therapy”; Speaker:  Tom White, Ph.D., Chief Scientific Officer, Senior Vice President, Celera Corporation

v      CACO, Wednesday Evening, Jan. 20, 2010—Event: “Poorly Soluble Drugs: Pharmaceutical Development Strategies and Approaches for Pre Clinical Applications (jointly with AAPS-BADG)”– Dinner Seminar; Speakers: K. Nagapudi, S. Nadkarni, S. Neeravannan

v      Engineering in Medicine and Biology Society (EMBS), Wed. Evening, Jan. 20, 2010—Topic:   “SMRT (Single-Molecule, Real-Time) Biology”; Speaker: Jonas Korlach, PhD, Principal Scientist, Pacific Biosciences

v      Palo Alto AWIS, Thursday Evening, Jan. 21, 2010—Topic: “Skills, Strategies & Super Powers for the 21st Century Woman”;  Speaker: Christine Arylo, Inspirational Catalyst, www.DareToLiveYou.com

v      San Jose BioCenter, Thursday Midday, Jan. 21, 2010—Topic: Grant Writing: A Business Development Workshop
Speakers:Shauna Farr-Jones, Ph.D. and Amy F. Boggs, Ph.D.

v      ACRP, Saturday Morning, Jan. 23, 2010–Event: Annual Chapter Planning Meeting: 23 January 2010

Listing of Courses (you can download a full brochure of winter courses at http://www.ucsc-extension.edu/biosciences):

v      UCSC Extension Courses Starting/Occurring Jan. 19 through Jan. 23

• Molecular Biology, Introduction, Jan. 19 – March 6
• Regulation of Medical Devices and Diagnostics, Jan. 19 – April 13
• Good Clinical Practices, Jan. 20 – March 31, 2010
• SAS Programming for Clinical Trials, Jan. 20 – March 31
• Human Physiology in Health and Disease, Jan. 21, -April 1, 2010
• Regulatory Submissions: Devices and Diagnostics, Jan. 21 – March 18
• Clinical Trials Site Monitoring I, Jan. 22 – Feb. 12
• Medical/Clinical Terminology, Saturday, Jan. 23, 2010

I’d like to make note of my upcoming business and marketing course, “Bioscience Product Marketing,” Thursday Evenings, Feb. 11 – March 25, 2010. Be sure to enroll prior to Jan. 29th to take advantage of the discount provided through that date. See details at www.ucsc-extension.edu/BPM

Be sure to add regular attendance and networking at industry events to your New Year’s resolutions.

Audrey

Hi,

There was good news about life science jobs in a report released by Gail Maderis, Acting Chief Executive of BayBio last Tuesday in San Francisco. Not far away over 6,500 bioscience investors and company professionals gathered for the world’s premier global healthcare conference, the JP Morgan 28^th Annual Healthcare Conference. Total life science jobs in Northern California increased from 127,241 in 2008 to 129,410 in 2009 at rate of 1.7% while more numerous jobs in Southern California also increased from 150,917 to 151,098 at rate of 0.1% in same years.

Source: BayBio 2010

This growth is amazing considering the layoffs of 5,500 in 2009 in 85 biotech companies nationally reported by BioWorld Insight staff reporter Trista Morrison on Jan. 11, 2010 and the ever steeper competition to attract companies and associated jobs in other regions of the country. The growth rate has slowed since the period 2003 to 2008 when the growth in bioscience jobs in Northern California was 3.2% compared to 2.3% in Southern California, but still is the only growth sector in California.

Gabrielle Lajoie, Managing Director with search firm Russell Reynolds Associates, who was interviewed by Ms. Morrison reported the industry hit a low point in February but as 2009 proceeded, hiring picked up with biotech hiring above average in the 4^th quarter of 2009. She reported the greatest hiring was coming from emerging growth public biotechs rather than pharma or big biotech firms and that hiring among venture-backed biotechs and startups was beginning to pick up as well.

The same pattern reported above was experienced in the sample of jobs that crossed my desk in 2009. I’m pleased to be able to post a healthy list of jobs that have surfaced in this year including the last week in December 2009 as a downloadable  file  for your review.  Jobs That Crossed My Desk Through Jan17_2010 (Right click on file and open in another window.)

Be sure to check other job listings on industry professional organization websites like Bio2Device Group for additional jobs.  Remember I only list those that come to me directly.

Audrey